Evidence map›Paper›PMID 32245130›Full record

ReviewBiomolecules2020

The Role of Nicotinamide in Cancer Chemoprevention and Therapy.

Ilias P Nikas, Stavroula A Paschou, Han Suk Ryu

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 133 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Ilias P NikasSchool of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.ORCID 0000-0001-8625-2556
Stavroula A PaschouSchool of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.ORCID 0000-0002-0651-1376
Han Suk RyuDepartment of Pathology, Seoul National University Hospital, Seoul 03080, Korea.ORCID 0000-0003-2508-9796
European University Cyprus · CYNational and Kapodistrian University of Athens · GRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicotinamide (NAM) is a water-soluble form of Vitamin B3 (niacin) and a precursor of nicotinamide-adenine dinucleotide (NAD

Indexed as

Clinical Trials, Phase III as TopicHumansNADNeoplasm ProteinsNeoplasmsNiacinamidePoly (ADP-Ribose) Polymerase-1Sirtuin 1NADNeoplasm ProteinsNiacinamidePARP1 protein, humanPoly (ADP-Ribose) Polymerase-1SIRT1 protein, humanSirtuin 1actinic keratosiscancer preventionchemotherapy resistanceNAD+ metabolismniacinamidenon-melanoma skin cancerONTRAC clinical trialPARP1radiotherapySIRT1

Identifiers

PMID32245130
PMCPMC7175378
OpenAlexW3011380189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.